Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Lupus: Treatment Pearls for the General Dermatology Clinic
Description
In a recent presentation on managing cutaneous lupus, Dr. Gallon Folk emphasized key strategies for dermatologists in a clinic setting. He discussed the critical role of photo protection, noting that patients with lupus should prioritize avoiding UV exposure, as it exacerbates both skin and systemic symptoms; recommended the use of broad-spectrum sunscreens (SPF 50 or higher) and protective clothing. Dr. Folk highlighted the importance of topical treatments along with the cornerstone of lupus management, hydroxychloroquine, urging practitioners to manage patient expectations regarding its delayed onset of action. He detailed dosing protocols to mitigate retinal toxicity risks and encouraged regular eye examinations. In cases of more severe cutaneous manifestations, he advocated for using DMARDs and glucocorticoids, particularly for aggressive or extensive skin disease, while also warning about the unique risks of bone loss in lupus patients. He later introduced newer treatments, including anafrolumab, which shows promise for recalcitrant conditions. Throughout the talk, Dr. Folk tailored his advice to address common pitfalls, including the importance of sun protection and the non-lupus skin issues that can complicate treatment. The interactive nature of his presentation engaged the audience and underscored the necessity of thorough, compassionate patient care in managing this chronic condition.
View moreConclusions
- Dermatologists play a crucial role in the management of lupus, which involves collaboration with rheumatologists when necessary.
- Photo protection is vital for lupus patients to avoid exacerbations caused by UV light exposure.
- Sunscreens with a minimum SPF of 50 are recommended as they provide better protection than lower SPF options.
- Physical blockers, like zinc oxide and titanium dioxide, are effective and often preferable due to cost and their range of UV protection.
- Topical treatments, such as fluorouracil and tacrolimus, are important adjuncts to systemic therapies and should not be discontinued when starting oral medications.
- Hydroxychloroquine is a cornerstone treatment for systemic and cutaneous lupus, requiring careful patient education regarding its effects and timing for efficacy.
- The use of DMARDs, such as methotrexate and mycophenolate, is indicated in severe cases or when first-line therapies are insufficient.
- New therapies, like anifrolumab, provide promising results for patients with resistant cutaneous lupus.
- Regular monitoring for ocular toxicity is essential for patients on hydroxychloroquine, particularly after five years of use.
- Smoking can worsen lupus symptoms and reduce the efficacy of treatments, making cessation a critical part of managing this condition.
- Chang J, Werth V. Expert Rev Clin Immunol. 2016;12(10):1109.
- Kuhn et al. JAAD. 2011;64(1):37.
- Ruland et al. Arth Care Res. 2013;65(5):767.
- Faurscho et al. Br J Derm. 2007;156:716.
- Roenigk et al. cutis. 1980;25(3):281.
- Pothinamthong et al. J Med Assoc Thailand. 2012;95(7):933.
- Kraak, vaketel, prakken et al. Dermatologica. 1965. 130:293-305.
- Callen. Arch Dermatol. 1982. 118:412-16.
- Wolverton. Comprehensive Dermatologic Drug Therapy. 2001. W.B. Saudners.
- Mittal L, Werth V. JAAD. 2017;77(2):374-7.
- Chang, Piette, Foering et al. Arch Dermatol. 2011;147(11):1261-7.
- Jallouli et al. JAMA Dermatol. 2013.149(8).
- Gaffney RG et al. JAAD Case Rep. 2023 Dec 16;44:71-73. PMCID: PMC10821374
- Viedma-Martínez M, et al. J Eur Acad Dermatol Venereol. 2023 Dec 30. doi: 10.1111/jdv.19755. Epub ahead of print. PMID: 38159281.
- Shaw KS et al. JAMA Netw Open. 2023 Oct 2;6(10):e2338200. PMCID: PMC10585408.
- Werth VP. Best Pract Res Clin Rheuamatol. 2013;27(3):391.
- Keyes E et al. J Am Acad Dermatol. 2022 Aug;87(2):447-448.